Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Hiroko Miyagi(University of Florida), Paul L. Crispen(University of Kentucky), Elizabeth P. Kwenda(University of Florida), Wayne Brisbane(University of California, Los Angeles), Jonathan Alexander Chatzkel(University of Florida), Brian Hemendra Ramnaraign(University of Florida Health), Padraic O’Malley(University of Florida)
Cited by 27
Related Papers
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
An overview of kidney stone imaging techniques
|Nature Reviews Urology|2016|389
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling
|European Urology|2022|169
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
|The Journal of Urology|2024|80
MicroSegNet: A deep learning approach for prostate segmentation on micro-ultrasound images
|Computerized Medical Imaging and Graphics|2024|76